Zolinza (Vorinostat) – CTCL | HongKong DengYue Medicine

  • Generic Name/Brand Name: ​Vorinostat / Zolinza®
  • Indications: CTCL
  • Dosage Form: ​ Capsule
  • Specification: 100 mg × 120 capsules/bottle
Category: Tag:

Vorinostat Application Scope

Zolinza is an oral histone deacetylase (HDAC) inhibitor that induces cell cycle arrest, differentiation, and apoptosis in malignant cells by altering gene expression.

Indications:

  • Cutaneous T-cell lymphoma (CTCL): For patients with progressive, persistent, or recurrent disease following at least two systemic therapies.

zolinza vorinostat
zolinza vorinostat

Vorinostat Characteristics

  • Ingredients: Active ingredient: Vorinostat
    Excipients: microcrystalline cellulose, magnesium stearate, sodium starch glycolate, etc.

  • Properties:​ White to off-white capsules.

  • Packaging Specification:​ 100 mg capsules, bottles of 120.

  • Storage:​ Store at 20–25°C. Protect from moisture.

  • Expiry Date: As indicated on package (24–36 months).

  • Executive Standard: ​Enterprise/regulatory authority standard.

  • Approval Number: Per FDA/NMPA/EMA records.

  • Date of Revision: As listed in insert.

  • Manufacturer: Merck & Co., Inc.

Guidelines for the Use of Zolinza

  • Dosage and Administration:

    • Recommended Dose: 400 mg orally once daily.

    • Administration: Swallow whole with food.

    • Missed Dose:​ Skip and take the next scheduled dose. Do not double dose.

  • Adverse Reactions:

    • Common Adverse Reactions:

      • Fatigue

      • Nausea, diarrhea, anorexia

      • Thrombocytopenia, anemia

      • Weight loss

    • Serious Adverse Reactions:

      • Pulmonary embolism, deep vein thrombosis

      • Severe thrombocytopenia or anemia

      • QT prolongation, cardiac events

      • Severe dehydration from GI toxicity

  • Contraindications:

    • Hypersensitivity to Vorinostat or excipients.

    • Pregnancy and breastfeeding.

  • Precautions:

    • Monitor CBC, electrolytes, ECG.

    • Use caution in patients with prior thromboembolic disease.

    • Ensure adequate hydration.

Vorinostat Interactions

  • Caution with anticoagulants (↑ bleeding risk).

  • May interact with other HDAC inhibitors (↑ toxicity).

  • CYP substrate interactions possible.

 

Note:

  • If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
  •  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.
Contact Us
Contact Form Demo